SWOG clinical trial number
CTSU/NRG-GU005
Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Open
Abbreviated Title
PIII IGRT and SBRT Vs IGRT and Hypofractionated IMRT
Status Notes
This study is active in SWOG effective October 1, 2019.
Activated
10/01/2019
Research committees
Genitourinary Cancer
Treatment
Radiation Therapy
Eligibility Criteria Expand/Collapse
Please see eligibility criteria in protocol on www.CTSU.org
Other Clinical Trials
SWOG Clinical Trial Number
S1937
A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.
Research Committee(s)
Genitourinary Cancer
Activated
02/16/2021
Accrual
0%
Open
Phase
III
SWOG Clinical Trial Number
CTSU/A031803
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Research Committee(s)
Genitourinary Cancer
Activated
01/06/2020
Open
SWOG Clinical Trial Number
CTSU/NRG-GU005
Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Research Committee(s)
Genitourinary Cancer
Activated
10/01/2019
Open